ArticleJournal of inflammation research2026
Astragaloside IV Modulates the Immune Response in Rheumatoid Arthritis and is Associated with Inhibition of the NAV2-Wnt/β-Catenin Signaling Cascade.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint destruction and systemic inflammation, with limited long-term efficacy and clinically important adverse effects of current treatments. Astragaloside IV (ASIV), the core active saponin component isolated from Objective: This study aimed to investigate whether ASIV alleviates RA by modulating the Methods: A collagen-induced arthritis (CIA) model was established in female Wistar rats. The animals were randomly divided into four groups (n=6 per group initially, final n=3 per group based on modeling success criteria): healthy controls (NOR group), CIA model (CIA group), methotrexate-treated (MTX group, positive control, 0.9 mg/kg/week), and ASIV-treated (ASIV group, 50 mg/kg/day). Following a 4-week intervention period initiated on day 14 post-primary immunization, we evaluated arthritis severity (arthritis scores, vs volume), bone microstructure (micro-CT), histopathological features (H&E, Safranin O, Masson, TRAP staining), and serum levels of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, IL-10, IL-13, detected by enzyme-linked immunosorbent assay (ELISA)) via abdominal aorta blood collection. Messenger RNA and protein expression levels of NAV2, Wnt3a, and β-catenin in the spleen and joint tissues were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC). All data were analyzed using GraphPad Prism 8.3.0. Normality and homogeneity of variances were verified before analysis; one-way ANOVA followed by Tukey's post-hoc test was applied for multiple group comparisons, and independent Results: Compared with the NOR group, rats in the CIA model group exhibited significant joint swelling, elevated arthritis scores, severe bone microstructure destruction, and disordered serum cytokine profiles, with increased pro-inflammatory factors (TNF-α, IL-1β, IL-6, IL-17A) and decreased anti-inflammatory factors (IL-10, IL-13) ( Conclusion: ASIV attenuated CIA-associated inflammatory and structural changes and was associated with reduced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.